U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Pfizer (PFE) wins Metsera (MTSR) buyout after a heated bidding war with Novo Nordisk (NVO), securing a $10B deal for the ...

By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera has accepted Pfizer's $10 billion acquisition ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

Pfizer’s lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong ...

El gigante farmacéutico estadounidense Pfizer firmó un acuerdo para adquirir Metsera Inc., la empresa desarrolladora de medicamentos ...

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk's unsolicited bid to acquire obesity biotech Metsera ...